1] Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany [2] Department of Developmental Genetics, Max-Planck-Institute for Molecular Genetics, Berlin, Germany.
Department of Developmental Genetics, Max-Planck-Institute for Molecular Genetics, Berlin, Germany.
Oncogene. 2015 Jun 11;34(24):3164-75. doi: 10.1038/onc.2014.247. Epub 2014 Aug 11.
Colon cancer cells frequently carry mutations that activate the β-catenin and mitogen-activated protein kinase (MAPK) signaling cascades. Yet how oncogenic alterations interact to control cellular hierarchies during tumor initiation and progression is largely unknown. We found that oncogenic BRAF modulates gene expression associated with cell differentiation in colon cancer cells. We therefore engineered a mouse with an inducible oncogenic BRAF transgene, and analyzed BRAF effects on cellular hierarchies in the intestinal epithelium in vivo and in primary organotypic culture. We demonstrate that transgenic expression of oncogenic BRAF in the mouse strongly activated MAPK signal transduction, resulted in the rapid development of generalized serrated dysplasia, but unexpectedly also induced depletion of the intestinal stem cell (ISC) pool. Histological and gene expression analyses indicate that ISCs collectively converted to short-lived progenitor cells after BRAF activation. As Wnt/β-catenin signals encourage ISC identity, we asked whether β-catenin activity could counteract oncogenic BRAF. Indeed, we found that intestinal organoids could be partially protected from deleterious oncogenic BRAF effects by Wnt3a or by small-molecule inhibition of GSK3β. Similarly, transgenic expression of stabilized β-catenin in addition to oncogenic BRAF partially prevented loss of stem cells in the mouse intestine. We also used BRAF(V637E) knock-in mice to follow changes in the stem cell pool during serrated tumor progression and found ISC marker expression reduced in serrated hyperplasia forming after BRAF activation, but intensified in progressive dysplastic foci characterized by additional mutations that activate the Wnt/β-catenin pathway. Our study suggests that oncogenic alterations activating the MAPK and Wnt/β-catenin pathways must be consecutively and coordinately selected to assure stem cell maintenance during colon cancer initiation and progression. Notably, loss of stem cell identity upon induction of BRAF/MAPK activity may represent a novel fail-safe mechanism protecting intestinal tissue from oncogene activation.
结直肠癌细胞常携带激活β-连环蛋白和丝裂原活化蛋白激酶 (MAPK) 信号通路的突变。然而,致癌改变如何相互作用以控制肿瘤起始和进展过程中的细胞层次结构在很大程度上仍是未知的。我们发现致癌 BRAF 调节与结直肠癌细胞分化相关的基因表达。因此,我们构建了一种可诱导表达致癌 BRAF 转基因的小鼠,并分析了 BRAF 在体内和原代器官型培养物中对肠道上皮细胞层次结构的影响。我们证明,在小鼠中转基因表达致癌 BRAF 可强烈激活 MAPK 信号转导,导致广泛锯齿状发育不良的快速发展,但出乎意料的是,也诱导了肠干细胞 (ISC) 池的耗竭。组织学和基因表达分析表明,ISC 集体转化为短暂的祖细胞后 BRAF 激活。由于 Wnt/β-连环蛋白信号鼓励 ISC 特性,我们询问β-连环蛋白活性是否可以拮抗致癌 BRAF。事实上,我们发现 Wnt3a 或通过小分子抑制 GSK3β 可部分保护肠道类器官免受致癌 BRAF 效应的有害影响。同样,在致癌 BRAF 表达的基础上表达稳定的β-连环蛋白也可部分防止小鼠肠道中干细胞的丢失。我们还使用 BRAF(V637E) 敲入小鼠来跟踪锯齿状肿瘤进展过程中干细胞池的变化,发现 BRAF 激活后形成锯齿状增生时 ISC 标记物表达减少,但在伴有激活 Wnt/β-连环蛋白途径的其他突变的进行性发育不良灶中增强。我们的研究表明,激活 MAPK 和 Wnt/β-连环蛋白途径的致癌改变必须连续且协调地选择,以确保结直肠癌起始和进展过程中干细胞的维持。值得注意的是,BRAF/MAPK 活性诱导时干细胞特性的丧失可能代表一种新的失效安全机制,可保护肠道组织免受致癌基因激活。